Efficacy and safety of nituzumab combined with albumin bound paclitaxel in treatment of pancreatic cancer
Objective:To evaluate the safety and efficacy of nituzumab combined with albumin bound paclitaxel in the treatment of pancreatic cancer.Methods:Ninety-six pancreatic cancer patients hospitalized at Affiliated Central Hospital of Jiangnan University from February 16, 2018 to December 16, 2021 were randomly and evenly divided into a control group (48 cases) and a combination group (48 cases) according to odd and even numbers. The control group was treated with albumin bound paclitaxel alone, and the combination group was treated with nituzumab combined with albumin bound paclitaxel. The treatment effect, disease control rate, serum tumor markers (CA19-9, CA125, CA50, and CEA), pain degree (VAS), survival rate, and safety evaluation (adverse reaction rate) were compared between the two groups before and after treatment.Results:The effective rate (60.42%) and disease control rate (75.00%) of the combination group were significantly higher than those of the control group (39.58% and 52.08%, respectively; P＜0.05), while the incidence of nausea, vomiting, and myelosuppression in the combination group was significantly lower than that of the control group (P＜0.05). Although there was no significant difference in the levels of CA19-9, CA125, CA50, and CEA between the two groups before treatment (P＞0.05), all of them decreased significantly in both groups after treatment, and were significantly lower in the combination group than in the control group (P＜0.05). There was no significant difference in VAS score between the two groups before treatment (P＞0.05), but VAS score decreased significantly in both groups after treatment and was significantly lower in the combination group than in the control group (P＜0.05). There was no significant difference in the survival rate between the two groups at 3, 6, and 9 months after treatment (P＞0.05), but the survival rate at 12 months after treatment was significantly higher in the combination group than in the control group (P＜0.05).Conclusion:For patients with pancreatic cancer, the combination of nifetazumab and albumin bound paclitaxel is significantly more effective than albumin bound paclitaxel alone, which can reduce the levels of tumor markers, reduce patients' pain, and improve survival rate and safety.
万方数据
